Prognostic factors for mortality in invasive pneumococcal disease in adult: a system review and meta-analysis

Hao, Chunyan; Matsumoto, Hiromi; Horita, Nobuyuki; Hara, Yu; Kobayashi, Nobuaki; Kaneko, Takeshi

doi:10.1038/s41598-021-91234-y

Cited by 43 publications

(35 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the IPD incidence has decreased in the adult population, the elderly and adults with underlying medical conditions are carrying an increased proportion of the remaining IPD burden in several settings [ 3 , 4 , 5 , 6 , 7 ]. These high-risk groups also have an increased risk of IPD-associated mortality, highlighting the importance of adequate preventive efforts by vaccination [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

The Risk of Invasive Pneumococcal Disease Differs between Risk Groups in Norway Following Widespread Use of the 13-Valent Pneumococcal Vaccine in Children

et al. 2021

View full text Add to dashboard Cite

The elderly and adults with medical risk conditions remain at high risk of invasive pneumococcal disease (IPD), highlighting the importance of adequate preventive efforts. In an observational population-based study in Norway (pop ≥ 5 years, 2009–2017) covering six years post-PCV13 implementation, we explored the incidence and risk of IPD associated with age and comorbidities. We obtained the data on 5535 IPD cases from the Norwegian Surveillance System for Communicable Diseases and the population data from Statistics Norway. To define comorbidities, we obtained ICD-10 codes from the Norwegian Patient Registry for the cases and the Norwegian population. The average annual decrease in PCV13 IPD incidence was significant in all risk groups and decreased post-PCV13 introduction by 16–20% per risk group, implying a nondifferential indirect protection from the childhood vaccination. The IPD incidence remained high in the medical risk groups. The relative importance of medical risk conditions was 2.8 to 6 times higher in those aged 5–64 versus ≥65 years for all types of IPD, since age itself is a risk factor for IPD. In groups without medical risk, the risk of IPD was eight times higher in those aged ≥65 compared to those 5–64 years (RR 8.3 (95% CI 7.3–9.5)). Our results underscore the need for age- and risk-group-based prevention strategies.

show abstract

Section: Introductionmentioning

confidence: 99%

The Risk of Invasive Pneumococcal Disease Differs between Risk Groups in Norway Following Widespread Use of the 13-Valent Pneumococcal Vaccine in Children

et al. 2021

View full text Add to dashboard Cite

show abstract

“…We examined the characteristics of IPDs in adults in our department. A systematic review and meta-analysis of IPD in adults by Chen et al 3) reported a mortality rate of 20.8%. They also reported that the factors associated with mortality were age, being in nursing home, nosocomial infections, septic shock, chronic diseases, solid organ tumor, immunosuppression, and alcohol abuse.…”

Section: Discussionmentioning

confidence: 99%

“…The fatality rate of IPD in adults has been reported to be between 10-15% 2) . Recently, Chen et al conducted a systematic review and meta-analysis of the prognostic factors for mortality in adults 3) . Our study aimed to determine the clinical characteristics of IPD in adults by comparing it with pneumococcal pneumonia.…”

Section: Introductionmentioning

confidence: 99%

Comparison of the clinical features of invasive pneumococcal disease with those of pneumococcal pneumonia in adults

et al. 2022

View full text Add to dashboard Cite

Background: Invasive pneumococcal disease (IPD) is an infectious disease where Streptococcus pneumoniae can be detected in the cerebrospinal fluid or blood. Methods: Eight patients presented to our hospital with adult IPD. We compared with 69 cases of pneumococcal pneumonia treated in our department between 2012 and 2014. None of the patients had a history of pneumococcal vaccine administration. Results: Hematological examination showed the platelet count was significantly lower and the serum C-reactive protein level was significantly higher in the IPD group. There was a significant difference in the use of a respirator and mortality in the IPD group. About antibiotics, Carbapenem and quinolone were used for the treatment of many patients in the IPD group. In the fatal three cases of IPD, the age of all members were 65 years or younger. Two of three had no underlying disease. Conclusion: IPD develops without elderly people and in those without underlying disease. Also, the patients who took a sudden course may result in death. In line with previous studies that have reported the effectiveness of the pneumococcal vaccine, our study findings emphasize the need of administering vaccination for prevention of IPD in person who was younger than 65 years old.

show abstract

“…A meta-analysis of 26 studies conducted in various countries reported the overall mortality rate due to IPD as 20.8%. Factors such as older age (>64 years old), septic shock, immunocompromising condition, underlying chronic diseases, solid organ tumors, alcohol abuse, nursing homes, and nosocomial infection were determined to be prognostic factors determining the mortality rate from IPD [ 7 ].…”

Section: Introduction—risk Of Pneumococcal Disease In Adultsmentioning

confidence: 99%

Pneumococcal Disease in High-Risk Adults in Lebanon: Expert Opinion

et al. 2022

View full text Add to dashboard Cite

Pneumococcal disease affects people across all ages but is more prevalent in young children and the elderly. Despite the availability of the pneumococcal vaccine for adults, the disease burden and mortality associated with it remains a challenge. A few studies conducted in Lebanon have reported epidemiology of pneumococcal disease, concurring the high burden among adults and older adults in the region. The pneumococcal vaccine is a part of the routine immunization schedule for children, but there are no recommendations for adult vaccination. A medical advisory board was hence conducted in September 2020 to discuss the burden of pneumococcal disease (PD) among adults in Lebanon. The participants were experts from the fields of internal medicine, family medicine, hematology, cardiology, oncology, endocrinology, pulmonology, and infectious diseases. The experts reached a consensus that there is a need to take steps to increase the rate of adult vaccination uptake and create awareness among physicians, pharmacists, caregivers, and patients. The physicians should be trained on adult immunization and should actively discuss the importance of the pneumococcal vaccine, especially with high-risk adult patients. Implementing adult vaccination as a routine practice and involving various stakeholders to address the gaps can help in reducing the burden of pneumococcal disease in adults.

show abstract

Prognostic factors for mortality in invasive pneumococcal disease in adult: a system review and meta-analysis

Cited by 43 publications

References 38 publications

The Risk of Invasive Pneumococcal Disease Differs between Risk Groups in Norway Following Widespread Use of the 13-Valent Pneumococcal Vaccine in Children

The Risk of Invasive Pneumococcal Disease Differs between Risk Groups in Norway Following Widespread Use of the 13-Valent Pneumococcal Vaccine in Children

Comparison of the clinical features of invasive pneumococcal disease with those of pneumococcal pneumonia in adults

Pneumococcal Disease in High-Risk Adults in Lebanon: Expert Opinion

Contact Info

Product

Resources

About